Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ ICU admission -404% Improvement Relative Risk Hospitalization -2% Recovery -16% Viral load 12% Viral clearance 14% c19nitazoxanide.com Rocco et al. Nitazoxanide for COVID-19 RCT EARLY TREATMENT Favors nitazoxanide Favors control
Rocco, 392 patient nitazoxanide early treatment RCT: 404% higher ICU admission [p=0.24], 2% higher hospitalization [p=1], 16% worse recovery [p=0.37], and 12% improved viral clearance [p=0.006] https://c19p.org/rocco
copied to clipboard
Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trial (preprint 10/23)
Rocco et al., European Respiratory Journal, doi:10.1183/13993003.03725-2020 (date from earlier preprint)
23 Oct 2020    Source   PDF   Share   Tweet
RCT 392 patients, median treatment delay 5 days, showing improved viral recovery at 5 days. Symptom recovery was no different at 5 days, and the treatment arm had two ICU admissions compared to zero for control. There were no serious adverse events.
risk of ICU admission, 404.1% higher, RR 5.04, p = 0.24, treatment 2 of 194 (1.0%), control 0 of 198 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), table S3.
risk of hospitalization, 2.1% higher, RR 1.02, p = 1.00, treatment 5 of 194 (2.6%), control 5 of 198 (2.5%), table S3.
risk of no recovery, 15.8% higher, RR 1.16, p = 0.37, treatment 59 of 194 (30.4%), control 52 of 198 (26.3%), day 5.
relative viral load, 12.1% better, RR 0.88, p = 0.006, treatment 194, control 198, day 5.
risk of no viral clearance, 14.3% lower, RR 0.86, p = 0.009, treatment 136 of 194 (70.1%), control 162 of 198 (81.8%), NNT 8.5, day 5.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rocco et al., 23 Oct 2020, Randomized Controlled Trial, Brazil, peer-reviewed, 29 authors, average treatment delay 5.0 days.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperNitazoxanideAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit